Home Add to Favorite Contact Submit  
           24 November, 2020


    
Category:  Press » Health & Fitness

 

Kiadis Pharma Announces ATIR Interim Clinical Results

Popularity:
         Views: 1294
2007-10-10 12:17:54     
Kiadis Pharma B.V.

Kiadis Pharma today announced interim results of a physician initiated European Phase II clinical study for its lead product ATIR. Professor Velardi from the University of Perugia in Italy presented the successful treatment of thirteen end stage blood cancer patients with a mismatched bone marrow transplantation during the 5th workshop on "Haploidentical Stem cell Transplantation" in Catania, Italy. The results are an important milestone in the development of ATIR as a revolutionary approach to provide a safe and potentially life-saving mismatched bone marrow transplantation as treatment option for end-stage blood cancer patients.

Bone marrow transplantations are currently limited because of the high risk of Graft versus Host Disease (GvHD). This is a severe and potentially life-threatening complication in which the donor immune cells recognize and attack the patient's tissues and organs. Therefore it is currently essential that the patient and donor blood systems (the human leukocyte antigens, HLA) are highly similar in order to reduce the chance of acute GvHD. As a consequence, bone marrow transplantations strongly rely on the availability of a matching donor. However, the timely availability of a matching donor is a limiting factor for many patients to receive a bone marrow transplantation. Kiadis Pharma's ATIR is under development to prevent acute GvHD by elimination of the immune cells causing acute GvHD. A successful development would enable the performance of mismatched donor transplantations, including donor immune cells that can fight infections and the cancer without causing GvHD complications. Because ATIR eliminates acute GvHD causing cells, the transplantation can be performed without the currently standard immune suppressant regime post transplantation. This subsequently allows the donor immune system to rapidly develop helping the patient to fight infections, another major life threatening complication of bone marrow transplantations.

Professor Velardi, a key opinion leader in the field of mismatched allogeneic transplantations, has presented the clinical results of thirteen end stage blood cancer patients who received bone marrow transplants from mismatched donors, including donor immune cells that are selectively depleted of acute GvHD causing cells using ATIR. No immune suppressants were used post transplantation as a standard regime. No patient has developed lethal acute Graft versus Host Disease, the major complication that prohibits the use of this treatment without ATIR. The patients rapidly developed a new donor immune system as assessed by the rapid expansion of immune cells in the patients. Detailed analysis revealed the presence of pathogen specific donor immune cells in the patients. In particular immune cells recognizing pathogenic fungi, like Aspergillus and viruses like Cytomegalovirus (CMV) could be detected post transplantation.

These specific pathogens are the major cause of death by infections after bone marrow transplantation. This shows that the ATIR treated immune cells are functional and could fight infections without causing lethal acute GvHD in these patients.

"Bone marrow transplantations are often the only treatment option left for end-stage blood cancer patients. But too many patients simply do not find a suitable matched donor in time," said Dr. Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia. "The interim results of our study show a rapid immune reconstitution in transplanted patients provided with ATIR treated immune cells from mismatched donors. Without ATIR treatment this would not be possible because of the high risk of acute Graft versus Host Disease (GvHD) with mismatched donor immune cells. This is obviously a very hopeful development for a large patient group."

The physician initiated European ATIR Phase II trial by Prof. Andrea Velardi, M.D. is the second clinical trial of ATIR for mismatched bone marrow transplantations. Kiadis Pharma conducts a company-sponsored trial ongoing in North America. Both trials aim to investigate the potential of ATIR to make the use of a mismatched bone marrow transplantation a feasible treatment for blood cancer patients who are not responding to other treatments and who do not have access to a matched donor in time. For these patients ATIR can enable a potentially life-saving transplantation.

"The broad endorsement of ATIR by key opinion leaders in this field is exemplified by the initiative of Professor Velardi," commented Dr. Manja Bouman, CEO Kiadis Pharma. "These excellent results in the Perugia trial provide Kiadis Pharma with important external validation."

About ATIR

ATIR is being developed to enable the use of a mismatched donor for an allogeneic bone marrow transplantation for end stage blood cancer patients. ATIR selectively eliminates from a mismatched graft the immune cells that cause acute Graft versus Host Disease, a severe and potentially lethal complication with allogeneic bone marrow transplantations.

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with four products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address high-unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, the Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com.

Specialized in: Kiadis Pharma
URL: http://www.kiadis.com
Print press release      Bookmark this page
Related Press releases 
Dr Leeds Introduces Telemedicine Services to Ensure Safe Treatment During the COVID-19 Pandemic (Popularity: ): Fort Lauderdale, FL - USA | June 3rd, 2020 -- The current pandemic due to COVID-19 has forced the world to go indoors by practicing social distancing and adhering to lockdown instructions globally. These are the times that call for solidarity and unity to fight the situation until the world comes back to its normal being. In such challenging times, the medical experts at Dr Leeds have introduced telemedicine in ...
The launch of Meddco Android App with new features to make healthcare affordable (Popularity: ): MUMBAI, India, 20 JULY, 2019 -​​​ Meddco.com® is pleased to announce the reintroduction of its Android and iOS Mobile App and its latest functionality which aims to improve the health of everyday people. The addition of new features made to the Android and iOS app will help patients compare the prices of different healthcare services and choose the most suitable one with a single click. Moreover, it includes dynamic pricing, ...
Bethesda MD In-Home Care Agency Educates Readers On Mental Exercises (Popularity: ): Rockville, Maryland ( press.abc-directory.com ) January 22, 2019 - Comfort Home Care, a Bethesda Maryland in-home care agency, released a guide for people with elderly loved ones outlining mental exercises for strengthening memory and cognition. The Maryland in-home care agency recommends that family members help elderly loved ones incorporate these exercises into their regular routines to promote better mental health.As our loved ones age, their mental abilities often decline. Reduced ...
What are Former NFL Players Doing for a Healthier Mind, Body and Soul? Dr. Moalemi of Empire Physical Medicine & Pain Management Joins the Team (Popularity: ): Mount Laurel, NJ - May 31, 2016 -- The NFL Alumni's mission is to serve, assist and inform members to enrich their post-NFL lives. The NFL Alumni care for kids and care for their own, enabling the members to connect with each other and contribute to the community through charitable programs.NFL players endure several injuries during their tenure. Over time they develop bodily aches and pains. The Optimal Wellness Challenge ...
Stay Fit & Healthy Launches New Website for Fitness Products & Services in San Jose (Popularity: ): San Jose, California- April 22, 2016- Stay Fit & Healthy, fitness expert in San Jose, California and provider of high performance fitness products in San Jose is thrilled to announce the launch of its completely new website at stayfitandhealthymelaleuca.com.The revitalized new website welcomes visitors and everyone looking for high quality and reliable fitness products including vitamins, muscle shakes, weight management products and energy drinks in San Jose and surrounding areas. ...

Press release home snapshot 


Related Business 
Randstad Interim Executives (Popularity: ): Randstad Interim Executives is the UK's leading company dedicated to providing Interim Management services to companies and finding interim jobs for qualified professionals. Randstad Interim Executives has an un-paralleled track record of more than 25 years within the Interim Management market.
Swiss Pharma Contract (Popularity: ): Specializes in clinical trials, providing services in clinical pharmacology (owned clinical research unit), clinical research (phases II to IV), data management, statistics, consulting, and project management.
DrugDev123.com (Popularity: ): Clinical pharma research and development. Includes access to clinical trial listings, jobs and investigator training.
Pharma Jobs (Popularity: ): Find latest clinical research Jobs in leading Companies at Medicaljobcity.com. View & Apply to Pharma jobs, nursing jobs, jobs in hospital. Post your resume now!
Pharma Industry (Popularity: ): PCD,PCD Pharma,Pharma PCD,Pharma Franchise,Franchise,Propaganda Distributor,Pharma Monopoly,Pharma Distributor,Pharma Business,Propaganda,Pharma Distribution,PCD Pharmaceuticals, Pharmaceutical Manufacturer, PCD Distributor
Karishma Pharma Machines/Karishma International (Popularity: ): Karishma Pharma is thriving on efficient leadership, engineering excellence, cutting technology and professional approach. We have established ourselves as one of the leading supplier of a variety of Pharma Machines and Pharma Equipment required for pharma production and packaging. We highly appreciate the contribution of our team and invest accordingly in our resources to maintain and upgrade systems in this fast changing world.
Axess (Popularity: ): Provides clinical data management, statistics and reporting quality services to the pharmaceutical industry. Also offers specialised recruitment service in the clinical trials arena, providing staff as an interim management project or direct recruitment into your organisation.
Science Recruitment Agency (Popularity: ): A leading provider of permanent and interim recruitment services to the life sciences industry.We focus on the source and supply of mid to upper level clinical, medical and regulatory specialists involved in drug discovery, clinical development and postapproval processes.
Iris Pharma (Popularity: ): Specializes in ophthalmology pre-clinical studies and offers full services with the departments of pre-clinical research, basic research and bio-analysis.
PCD Pharma Company,PCD Pharma India,PCD Pharma Ahmedabad,PCD Pharma Franchise (Popularity: ): PCD Pharma India offers integrated manufacturing,marketing,and distribution of nearly 400+ products. Having one of the largest range of PCD pharma products to offer in India, we have a strong franchisee network of dedicated distributors. This makes us arguably one of the leading and most aggressive companies in the competitive PCD pharmacy domain based out of Ahmedabad and serving the requirements of distributors across Gujarat and India.